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Background: This study aimed to investigate whether hemodialysis (HD) affects tissue factor (TF), tissue 
factor pathway inhibitor (TFPI), and polymorphonuclear elastase (PMNE) in endstage renal disease (ESRD) 
patients when eliminating the effects of heparin. Also, to explore the interaction of TF, TFPI, and PMNE 
throughout a single HD session.
Methods: We enrolled 57 ESRD patients who had undergone hemodialysis for >3 months as an 
experimental group. Plasma levels of TF, TFPI and PMNE were measured by ELISA in 24 ERSD patients 
on intermittent HD using low-molecular-weight heparin (LMWH) as anticoagulation (LMWH group) and 
33 ESRD patients using citrate as anticoagulation (citrate group) at the start and at 1, 2 and 5 h of the HD 
session. Meanwhile,28 ESRD patients not on dialysis were enrolled as a control group and fasting venous 
blood samples were taken in the morning.
Results: Compared with the control group, the plasma TFPI levels of the LMWH group and the citrate 
group were significantly higher (P=0.000, P=0.002, respectively) under baseline conditions as well as the 
plasma PMNE levels (P=0.001, P=0.02,respectively), whereas TF showed no difference (P=0.186). During 
HD with citrate, plasma TFPI decreased slightly (P=0.012) and PMNE increased significantly (P=0.008) 
at 1 h. The plasma TFPI levels of the citrate group correlate with PMNE at 2 and 5 h (P=0.001, P=0.008, 
respectively).
Conclusions: ESRD patients on HD have significantly higher TFPI and PMNE levels compared to 
patients not on HD under baseline conditions, while TF levels were similar between the three groups. TFPI 
and PMNE are differently regulated, but the plasma levels correlated during HD in the citrate group. It 
might be possible that PMNE plays a role in anticoagulative activity through TFPI.
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Introduction
As the incidence of chronic kidney disease (CKD) steadily 
increase worldwide, hemodialysis (HD) is widely used 
for treating end-stage renal disease (ESRD). Adequate 
anticoagulation is a prerequisite for HD both to prevent 
clotting in the extracorporeal circuit (1), influencing the 
safety and efficacy of HD therapy. In China, there are 
three common anticoagulation means clinically, including 
unfractionated heparin (UFH), low-molecular-weight 
heparin (LMWH), and ‘no heparin,’ where LMWH is the 
prioritized option in maintenance HD. However, CKD 
patients already have an increased risk of excess bleeding, 
such as platelet dysfunction caused by uremia (2,3), let alone 
the potentially fatal heparin-induced thrombocytopenia type 
II and ‘no heparin’-induced consumption of platelet when 
receiving dialysis (4,5). Regional citrate anticoagulation 
has been tested on dialysis, but it might lead to potentially 
disastrous complications, such as citrate accumulation 
presenting metabolic acidosis, hypernatremia, and citrate 
net overload presenting metabolic alkalosis (6). The use of 
anticoagulation during HD remains a problem for ESRD 
patients with a high risk of bleeding complications. A new, 
safer, and more effective anticoagulation mean in HD is 
required.
Recently, many scholars have focused on tissue 
factor (TF), which initiates the extrinsic pathway of 
blood coagulation (4) and plays an important role in 
atherosclerosis (7,8). It was recently reported that adherent 
cells from the dialysis membrane were mainly constituted 
by activated polymorphonuclear neutrophils (PMNs), 
which triggered thrombin generation in a TF-dependent 
manner (9). The tissue factor pathway inhibitor (TFPI) is 
the only endogenous protein that effectively inhibits TF-
factor VIIa in a factor Xa-dependent manner and dampens 
the activation of clotting through the extrinsic pathway 
under physiological conditions (10,11). Moreover, the 
serine proteases enhance TF- and factor XII-dependent 
coagulation in a process involving local proteolysis of 
the coagulation suppressor TFPI (12,13). Noteworthy, 
both UFH and LMWH induced a significantly enhanced 
secretion of TFPI (14) and the aggregation of human 
PMNs (15,16).
This study aims to investigate, excluding the effect of 
heparin on TFPI and PMNs, whether HD affects the level 
of TF, TFPI, and polymorphonuclear elastase (PMNE) in 
ESRD patients. Also, to analyze the reaction of TF, TFPI, 
and PMNE in ESRD patients throughout a single HD 
session and to explore whether TF or TFPI can be a new 
target for HD anticoagulation.
Methods
Study population
Thirty-three selected ESRD patients (CKD5d), who had 
already undergone hemodialysis for >3 months and used 
citrate for anticoagulation for >3 days, were enrolled 
in the study (citrate group). They were compared with 
age, sex and etiology-matched ESRD patients who had 
undergone hemodialysis for >3 months using LMWH as 
anticoagulation (LMWH group) (n=24) and those who had 
never received dialysis (control group) (n=28). Each case of 
ESRD was diagnosed with the calculated estimated glomerular 
filtration rate (eGFR) <10 mL/min/1.73 m2 using the 
simplified Modification of Diet in Renal Disease (MDRD) 
formula and was present for >3 months (17). Subjects were 
excluded from the study if they presented with any of the 
following diseases: malignancy, hyperlipidemia (cholesterol 
concentrations >6.21 mmol/L), advanced liver disease, 
contraceptive, or blood transfusion within three days before 
the study. The etiology of ESRD patients are displayed in 
Table 1.
The study was approved by the Research Ethics 
Committee of West China Hospital of Sichuan University 
(2016-188), and informed consent was obtained from all 
participants.
Dialysis details
Hemodialysis was applied using a temporary femoral 
venous catheter (n=36) or a permanent internal jugular 
venous cuff catheter (n=21). All these patients used 
polyacrylonitrile (AN69) as the dialysis membrane and were 
maintained on low-flux (130–200 mL/min) intermittent 
renal replacement therapy. For the citrate group, anticoagulation 
was carried out using sodium citrate (4.0%) continuously infused 
at a speed of 130–200 mL/h and extra sodium bicarbonate 
(5%) at 100–170 mL/h. For the LMWH group, a single 
i.v. bolus of LMWH at the start of hemodialysis (range, 
1,000–2,500 IU) was followed by a constant infusion 
(range, 100–250 IU) and extra sodium bicarbonate (5%) 
at 190–260 mL/h. There were two dialysis patterns: day-
time continuous veno-venous hemodialysis (CVVHD) and 
day-time continuous veno-venous hemodialysis filtration 
(CVVHDF) (Table 1). Correspondingly, the displacement 
velocity was 1,500/1,500 mL/h and 3,000 mL/h, and all 
adopted post-dilution.
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Blood collection
Blood samples from hemodialysis patients were collected 
before a single dialysis session and at hours (h) 1, 2, and 
5 during the hemodialysis. Residual containing fluid was 
removed from catheters before collection of the first sample. 
When collecting blood samples during the hemodialysis, 
we shut off the peripheral pump of the dialyzer for 3 min 
except for the blood pump and then collected blood samples 
directly from the arterial line on the machine. Fasting 
venous blood samples were taken from the antecubital 
vein in the morning from the control of ESRD patients. 
Citrated-plasma samples were prepared conventionally, 
centrifuged (15 minutes, 3,000× g), aliquoted and stored at 
−80 ℃ until the assay.
Analytical procedures
Plasma levels of TF and TFPI were measured in duplicate 
by enzyme-linked immunosorbent assays (ELISA) using 
commercially available standard kits supplied by R&D 
Systems, Inc., USA. The plasma level of PMNE was 
measured by ELISA kit purchased from Life Technologies, 
Carlsbad, USA.
Statistical analysis
Quantitative data followed the normal distribution and were 
expressed as the mean ± SD (standard deviation) in tables 
or mean ± SEM (standard error of the mean) in figures. 
Characteristics of the participants were first presented as 
numbers and percentages. The data obtained at different 
time points were corrected by hematocrit. Chi-square test, 
one-way analysis of variance (one-way ANOVA) or Mann 
Whitney U test were used to adjust models controlling 
for sex, etiology, and age. Comparisons of the TF, TFPI, 
and PMNE plasma levels between the three groups and 
the levels at different time points were performed using 
one-way analysis of variance or Kruskal-Wallis H test. 
Bivariate correlation analysis was applied to explore the 
association between measured plasma constituents before 
hemodialysis and clinical indexes and the correlation of 
TF, TFPI, and PMNE plasma levels at each time point 
during hemodialysis. All statistical analyses were performed 
using IBM SPSS software SPSS 24. P<0.05 was considered 
statistically significant.
Table 1 Demographic and clinical characteristics
Studied parameters
ESRD patients without 
hemodialysis
ESRD patients with hemodialysis
P
Hemodialysis with LMWH Hemodialysis with citrate
Males/females (N) 22/6 19/5 24/9 0.810†
Age (years) 49.49±15.22 54.42±13.64 57.8±16.5 0.115*
Cause of ESRD (N (%)) 0.780†
Chronic glomerulonephritis 12 (42.9) 10 (41.7) 15 (45.5)
Interstitial nephritis 0 (0) 2 (8.3) 2 (6.1)
Polycystic kidney 1 (3.6) 0 (0) 0 (0)
Diabetic nephropathy 6 (21.4) 4 (16.7) 8 (24.2)
Hypertensive nephropathy 3 (10.7) 3 (12.5) 1 (3.0)
Unknown 6 (21.4) 5 (20.8) 7 (21.2)
Hemodialysis duration (months) – 33.18±31.76 29.1±33.9 0.117‡
Hemodialysis pattern (N) 0.776†
CVVHDF – 14 18
CVVHD – 10 15
ESRD, end-stage renal disease; LMWH, low-molecular-weight heparin; CVVHDF, day-time continuous veno-venous hemodiafiltration; 
CVVHD, day-time continuous veno-venous hemodialysis. Characteristics of the participants were presented as number and percentage. A 
comparison is made by one-way analysis of variance*, Chi-square test†or Mann Whitney U test‡.
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Results
ESRD patients’ demographic characteristics did not differ 
significantly between the three groups (Table 1). Compared 
with the control subjects, patients on hemodialysis with 
LMWH and citrate showed significant higher plasma 
concentrations of TFPI (P=0.000, P=0.002, respectively) 
and PMNE (P=0.001, P=0.02, respectively) under baseline 
conditions (Figure 1). However, TF plasma levels (P=0.186) 
between the three groups were similar (Figure 1A). Also, 
we found under baseline conditions that the cholesterol of 
ESRD patients in the citrate group was lower than that of 
the control group, including total cholesterol (P=0.002), 
high-density lipoprotein cholesterol (HDL-C) (P=0.009), 
and low-density lipoprotein-cholesterol (LDL-C) (P=0.000). 
The clinical indexes of the studied groups are shown in 
Table 2.
The results of factors correlating with plasma TF, TFPI, 
and PMNE levels in ESRD patients before hemodialysis 
are presented in Tables 3,4. We did not find any correlation 
between the pre-dialysis TF, TFPI, PMNE levels, and 
clinical indexes in the LMWH group (Table 3). However, in 
the citrate group, the pre-dialysis TF level was significantly 
correlated to glucose and monocyte % (r =0.345 and r 
=0.355, respectively; P<0.05). Also, the pre-dialysis TFPI 
level was positively associated with cholesterol (r =0.406, 
P=0.019) and LDL-C (r =0.490, P=0.004), whereas we did 
not find any clinical index that was correlated to the PMNE 
level before hemodialysis (Table 4).
As the different time points were measured, presented in 
Table 5, showed that the plasma levels of TFPI and PMNE 
fluctuated obviously (P=0.000, P=0.000, respectively) during 
HD with LMWH, but TF did not change significantly 
(P=0.935). Further analysis showed that plasma TF 
levels did not vary obviously (Figure 2A); plasma TFPI 
levels ascended significantly at 1 h (P=0.000), descended 
slightly at 2 h (P=0.364) and significantly at 5 h (P=0.000) 
(Figure 2B); the plasma levels of PMNE increased 
significantly at 1 h (P=0.000) and continued to rise at 2 h 
but did not reach a significant level (P=1.000) (Figure 2C). 
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Figure 1 The measured plasma constituents of ESRD patients with hemodialysis were obtained before a single dialysis session. (A) Comparison 
of plasma TF between three groups shows no difference. (B) Plasma TFPI in hemodialysis patients is higher than that of patients without 
hemodialysis. (C) Plasma PMNE in patients with hemodialysis with citrate is higher than that of patients without hemodialysis. Values are 
expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001; a comparison is made by one-way analysis of variance or Kruskal-Wallis H test. 
ESRD, endstage renal disease; TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase.
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The trends of TF, TFPI and PMNE in the LMWH group 
were shown in Figure 2D. For the citrate group, we found 
that the plasma levels of PMNE had changed significantly 
throughout hemodialysis (P=0.000), but the overall changes 
of TF (P=0.986) and TFPI (P=0.088) did not reach 
statistical significance (Table 6). Further analysis found that 
the change of plasma TF levels was not obvious, either 
(Figure 3A); plasma TFPI levels declined modestly at 1 h 
(P=0.012) (Figure 3B); the plasma levels of PMNE increased 
significantly at 1 h (P=0.008) and continued to rise at 2 h 
Table 2 Laboratory data 
Measured Plasma Constituents
ESRD patients without 
hemodialysis
ESRD patients with hemodialysis 
P
Hemodialysis with LMWH Hemodialysis with citrate
TF(pg/ml) 82.96±18.24 88.84±16.89 91.58±18.51 0.186††
TFPI(ng/ml) 26.41±12.79 119.79±21.04* 44.80±10.22*† 0.000††
PMNE(ng/ml) 33.10±20.87 50.69±18.98* 47.01±23.31* 0.001††
Creatinine (µmol/L) 721.39±162.2 493.96±286.03* 430.97±262.49* 0.000**
Cystatin C (mg/L) 4.40±0.95 4.63±2.02 4.13±1.39 0.450**
MONO% 6.38±2.09 6.64±3.82 6.15±2.80 0.826**
Triglyceride (mmol/L) 1.83±1.11 1.99±1.34 1.56±0.99 0.464††
Cholesterol (mmol/L) 3.84±1.29 3.41±0.99 2.77±0.80* 0.002††
HDL-C (mmol/L) 1.10±0.37 0.90±0.44 0.79±0.44* 0.012††
LDL-C (mmol/L) 2.17±1.06 1.67±0.86 1.19±0.63*† 0.000**
ESRD, end-stage renal disease; LMWH, low-molecular-weight heparin; TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, 
polymorphonuclear elastase; MONO%, the count of monocyte/the count of white blood cell%; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol. The values of ESRD patients with hemodialysis were obtained before a single 
dialysis session. Values are expressed as mean ± SD; a comparison is made by one-way analysis of variance** or Kruskal-Wallis H test††. 
*P < 0.05 compared with the control group, †P<0.05 compared with the LMWH group.
Table 3 Correlation of clinical indexes and TF, TFPI and PMNE levels of ESRD patients on hemodialysis with LMWH
Laboratory results
Pre-dialysis TF Pre-dialysis TFPI Pre-dialysis PMNE
r P r P r P
Glucose (mmol/L) 0.215 0.313 0.105 0.624 0.241 0.256
Albumin (g/L) −0.051 0.814 0.214 0.315 0.126 0.556
MONO% 0.044 0.840 0.030 0.890 −0.274 0.194
Creatinine (µmol/L) −0.153 0.476 0.142 0.509 0.074 0.731
Cystatin C (mg/L) −0.139 0.516 0.100 0.643 0.265 0.211
BUN (mmol/L) 0.074 0.733 0.126 0.558 0.404 0.050
Triglyceride (mmol/L) 0.214 0.315 -0.096 0.656 0.178 0.406
Cholesterol (mmol/L) −0.248 0.243 0.129 0.548 0.063 0.771
HDL-C (mmol/L) −0.086 0.691 0.084 0.696 −0.157 0.464
LDL-C (mmol/L) −0.348 0.096 0.229 0.281 −0.010 0.963
TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase; MONO%, the count of monocyte/the count of 
white blood cell%; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Values are expressed as mean 
± SD. A correlation is made by bivariate correlation analysis.
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but did not reach statistical significance (P=1.000), then 
descended slightly at 5 h (P=1.000) (Figure 3C). The trends 
of TF, TFPI and PMNE in the citrate group were shown in 
Figure 3D.
We used bivariate correlation analysis to explore the 
correlation of TF, TFPI, and PMNE plasma levels at each 
time point during hemodialysis. There was a possible 
correlation between TFPI levels and PMNE levels 
throughout the hemodialysis session with citrate, especially 
at 2 h (r =0.534, P=0.001) and 5 h (r =0.456, P=0.008), as 
shown in Figure 4. Furthermore, the change of the plasma 
PMNE level between 0 and 1 h was associated with the 
change of the plasma TFPI level between 0 h and 1 h 
(r =0.454, P=0.008) (Figure 4C). However, there was no such 
change and correlation for TF and the LMWH group.
Also, we divided the experimental group into CVVHD 
group and CVVHDF group according to the different HD 
modes and analyzed whether there were differences in TF, 
TFPI and PMNE plasma levels at different time points in 
the dialysis process between the two groups. No significant 
difference was found between CVVHD and CVVHDF 
groups.
Discussion
The major finding of the present study is that hemodialysis 
affected the plasma levels of TFPI and PMNE of ESRD 
patients but had minimal effect on plasma TF. Moreover, 
we found that, excluding the effect of heparin on TFPI and 
PMNs, PMNE might play a role in anticoagulative activity 
through TFPI during hemodialysis.
Numerous studies indicate that, compared to healthy 
Table 4 Correlation of clinical indexes and TF, TFPI and PMNE levels of ESRD patients on hemodialysis with citrate
Laboratory results
Pre-dialysis TF Pre-dialysis TFPI Pre-dialysis PMNE
r P r P r P
Glucose (mmol/L) 0.345 0.049* −0.044 0.807 0.075 0.678
Albumin (g/L) 0.219 0.221 0.203 0.257 −0.101 0.578
MONO% 0.355 0.043* 0.178 0.321 −0.228 0.201
Creatinine (µmol/L) 0.110 0.543 −0.240 0.178 −0.006 0.972
Cystatin C (mg/L) 0.085 0.638 0.042 0.815 −0.012 0.945
BUN (mmol/L) 0.328 0.063 −0.235 0.188 −0.052 0.773
Triglyceride (mmol/L) −0.042 0.817 −0.130 0.471 0.316 0.074
Cholesterol (mmol/L) 0.282 0.111 0.406 0.019* −0.063 0.729
HDL-C (mmol/L) 0.177 0.325 0.156 0.386 −0.170 0.345
LDL-C (mmol/L) 0.214 0.232 0.490 0.004** −0.053 0.768
TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase; MONO%, the count of monocyte/the count of 
white blood cell%; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Values are expressed as mean 
± SD. *P<0.05, **P<0.01; a correlation is made by bivariate correlation analysis.
Table 5 Variation of plasma TF, TFPI and PMNE levels during hemodialysis with LMWH
Variables
Measured Plasma Constituents During Experiments
P
0 h 1 h 2 h 5 h
TF (pg/mL) 88.84±16.89 92.30±25.79 91.88±21.30 89.89±20.59 0.935*
TFPI (ng/mL) 119.79±21.04 302.28±23.35 293.89±24.76 158.95±49.56 0.000*
PMNE (ng/mL) 50.69±18.98 98.30±47.74 119.86±69.48 95.88±49.28 0.000†
TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase. Values are expressed as mean ± SD. All the 
data are corrected by hematocrit. The analysis is done by one-way analysis of variance* or Kruskal-Wallis H test†.
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volunteers, plasma levels of TF and TFPI are higher in 
patients undergoing maintenance hemodialysis therapy 
(18-20). However, the variation of TF plasma levels 
during hemodialysis is inconsistent, as TF levels at times 
increase (21) or do not (18,19). It is contentious whether 
dialysis affects TF. Our study demonstrated that there 
was no difference in TF levels between ESRD patients 
with or without hemodialysis and that the TF plasma 
levels didn’t change during HD no matter what category 
of anticoagulation was adopted. These data suggest that 
a decreased kidney function is associated with increased 
TF levels, but not HD. TF is associated with enhanced 
oxidative stress (22,23), endothelial injury (24) and 
uremic solutes (25,26) in chronic kidney disease. A recent 
article reported that advanced oxidation protein products 
(AOPPs) and serum TF correlate with kidney function. 
ESRD patients who are on HD had significantly higher 
serum levels of AOPPs and TF compared to patients after 
kidney transplantation with a decent GFR (27). The study 
indicated that TF was still strongly associated with oxidative 
stress caused by renal insufficiency in HD patients. It 
was reported that the dialyzer membrane triggered TF 
Figure 2 Variation of plasma TF, TFPI and PMNE levels at different points during hemodialysis with LMWH. (A) Variation of plasma TF 
levels at different time points during hemodialysis with LMWH shows no difference. (B) Plasma TFPI increases significantly at 1 h. (C) 
Plasma PMNE increases significantly at 1 h. (D) Variation trends of TF, TFPI, PMNE during hemodialysis. Values are expressed as mean ± 
SEM. All the data are corrected by hematocrit. ***P<0.001; a comparison is made by one-way analysis of variance or Kruskal-Wallis H test. 
TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase; LMWH, low-molecular-weight heparin.
Table 6 Variation of plasma TF, TFPI and PMNE levels during hemodialysis with citrate
Variables
Measured Plasma Constituents During Experiments
P
0 h 1 h 2 h 5 h
TF (pg/mL) 91.58±18.51 92.26±19.05 92.99±18.78 93.13±19.55 0.986*
TFPI (ng/mL) 44.80±10.22 38.13±9.45 41.51±10.52 42.46±12.20 0.088*
PMNE (ng/mL) 47.01±23.31 85.98±54.66 100.15±68.95 88.00±60.41 0.000†
TF, tissue factor; TFPI, tissue factor pathway inhibitor; PMNE, polymorphonuclear elastase. Values are expressed as mean ± SD. All the 
data are corrected by hematocrit. The analysis is done by one-way analysis of variance*or Kruskal-Wallis H test†.
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expression of activated PMNs (9), but, in our study, the 
plasma levels of TF were not correlated with PMNE, which 
was a marker of activated PMNs. A possible reason for this 
phenomenon could be that TF was expressed richly enough 
because of renal insufficiency; consequently, the effect of 
dialysis on the tissue factor is weak. Thus, we speculate 
that the change in plasma TF level may be associated with 
chronic renal failure superior to HD. Also, the TF level 
of pre-dialysis was correlated with glucose and MONO%, 
which is similar to that of previous studies (10).
Several studies found that TFPI levels tended to rise 
significantly from minute 15 and minute 60 onward during 
hemodialysis (21,28,29), which is similar to the trend of 
the LMWH group in our study. There is no doubt that 
the use of heparin can significantly increase the TFPI level 
in hemodialysis patients. On the contrary, in the citrate 
group of our research, the plasma TFPI level decreased 
slightly at 1 h. It is noteworthy that all the previous studies 
used heparin for anticoagulation, while we used citrate. No 
literature has reported that citrate may affect TFPI, so it is 
considered that HD may affect the plasma levels of TFPI of 
ESRD patients itself, and the plasma TFPI level decreased 
during hemodialysis when using citrate for anticoagulation. 
Our study indicated that the pre-dialysis plasma level of 
TFPI was slightly higher in ESRD patients of the citrate 
group than that in controls. This may be due to the 
coagulation disorders in patients of the citrate group after 
receiving long-term hemodialysis. During hemodialysis, 
the anticoagulant effect of heparin is approximately 30%, 
mediated by the TFPI released from its endothelial stores 
into the circulating blood, which will lead to untoward 
depletion of TFPI (30,31). Repeated and continuous 
heparin administration will lead to excessive depletion of 
intravascular pools of TFPI, thereby resulting in attenuation 
of its contribution to the antithrombotic action of 
heparin (32) and protective effect on atherosclerosis. 
However, the results should be viewed with caution because 
the effect of dialysis cannot be ruled out.
The hemodialyzer membrane activates PMNs and 
promotes the release of PMNE (33,34). PMNE is a marker 
of the biological incompatibility of the dialyzer. Heparin is 
reported to stimulate PMNs in synergy with the stimulatory 
effect of dialysis membranes in vivo (35), which is similar to 
the PMNE changes in the LMWH group in our research. 
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Meanwhile, the PMNE changes of the citrate group in 
our study reconfirmed that when eliminating the effect 
of heparin, hemodialysis itself also stimulated PMNs and 
elevated the PMNE level. PMNE was considered to reflect 
adequate anticoagulative activity, as when anticoagulation 
was inadequate, the elastase values rose consistently (36). 
TFPI, as the unique inhibitor of the extrinsic coagulation 
pathway, plays an important part in defending thrombosis 
during hemodialysis (37). Recently, Massberg et al. bred 
mice with injured carotid arteries that were deficient in 
PMNE and cathepsin G (Elane−/−; Ctsg−/− mice), attesting 
that PMNE inactivated TFPI by involving local proteolysis 
of TFPI and then sequentially promoted intravascular 
thrombus growth in vivo (12). In our study, we also found 
a possible correlation between the plasma level of TFPI 
and PMNE during a heparin-free hemodialysis session. 
We didn’t find such correlation in the LMWH group 
probably because heparin has a great influence on TFPI 
but a little influence on PMNE, which is mainly affected by 
hemodialyzer membrane. The present study suggests that 
when eliminating the effect of heparin on TFPI and PMNs, 
PMNE might play a role in anticoagulative activity through 
TFPI during hemodialysis. 
The study, however, also bears some limitations. 
Although plasma levels of TF and TFPI can represent for 
their content in the body, alternatively spliced isoforms of 
TF and TFPI are differentially expressed by endothelial 
cells and human platelets (10,38). We only measured the 
plasma level of TF and TFPI, and it exists with some 
limitations. A prospective cohort study with a large number 
of hemodialysis subjects and direct biochemical research is 
required to confirm our results.
In conclusion, the change in the plasma TF level during 
HD is associated with chronic renal failure superior to 
HD. When eliminating the effect of heparin, hemodialysis 
can reduce the plasma concentration of TFPI, and PMNE 
might play a role in anticoagulative activity through TFPI 
during HD. Increasing or maintaining TFPI concentration 
may be a new target for anticoagulation and improving the 
biocompatibility of the hemodialysis membrane during 
hemodialysis, especially in ESRD patients with a high risk 
of bleeding complications.
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